Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001025571 | SCV001187784 | uncertain significance | Hereditary cancer-predisposing syndrome | 2019-03-02 | criteria provided, single submitter | clinical testing | The p.E224G variant (also known as c.671A>G), located in coding exon 5 of the TP53 gene, results from an A to G substitution at nucleotide position 671. The glutamic acid at codon 224 is replaced by glycine, an amino acid with similar properties. This variant was shown to have transactivation capabilities similar to wild type in yeast based functional studies (Kato S et al. Proc. Natl. Acad. Sci. USA. 2003 Jul 8;100(14):8424-9). Studies conducted in human cell lines indicate this alteration remains proficient at growth suppression (Kotler E et al. Mol. Cell 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Baylor Genetics | RCV003467686 | SCV004206218 | uncertain significance | Adrenocortical carcinoma, hereditary | 2023-10-18 | criteria provided, single submitter | clinical testing |